PATENT CLAIM ANALYSIS

Application Number: 16134070
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "136100"]

Abstract:
Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

Claim (Index 26):
The method of  claim 25 , wherein the subject has a PD-L1+/DespR+ tumor; increased levels of circulating or tumor DEspR+ neutrophils; increased levels of DEspR+ activated neutrophils; increased levels of NETs; increased plasma levels of neutrophil elastase (NE); increased plasma levels of neutrophil myeloperoxidase (MPO); or a tumor comprising one or more of:\n DEspR+ neutrophils; DEspR+ NETosing neutrophils; NETs; an increased level of a neutrophil released immune-suppressor; an increased level of citrullinated-histone-3; and increased level of a neutrophil stimulator.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.91837
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15129956', '15704344', '15441982', '14995679', '14746997']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7275264720003679
- 35 USC 102 Novelty (BERT): 0.5221964763363001
- Combined Prediction Score: 0.706993472433961
- Mean Citation Score: 285.856596
- Max Citation Score: 313.76178
- Similarity Product: 190.86311432044744

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test